These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 33183125

  • 1. Occurrence and microstructural features of slowly expanding lesions on fingolimod or natalizumab treatment in multiple sclerosis.
    Preziosa P, Pagani E, Moiola L, Rodegher M, Filippi M, Rocca MA.
    Mult Scler; 2021 Sep; 27(10):1520-1532. PubMed ID: 33183125
    [Abstract] [Full Text] [Related]

  • 2. Slowly Expanding Lesions Predict 9-Year Multiple Sclerosis Disease Progression.
    Preziosa P, Pagani E, Meani A, Moiola L, Rodegher M, Filippi M, Rocca MA.
    Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35105685
    [Abstract] [Full Text] [Related]

  • 3. Effects of Fingolimod and Natalizumab on Brain T1-/T2-Weighted and Magnetization Transfer Ratios: a 2-Year Study.
    Preziosa P, Storelli L, Meani A, Moiola L, Rodegher M, Filippi M, Rocca MA.
    Neurotherapeutics; 2021 Apr; 18(2):878-888. PubMed ID: 33483938
    [Abstract] [Full Text] [Related]

  • 4. Slowly expanding lesions relate to persisting black-holes and clinical outcomes in relapse-onset multiple sclerosis.
    Calvi A, Tur C, Chard D, Stutters J, Ciccarelli O, Cortese R, Battaglini M, Pietroboni A, De Riz M, Galimberti D, Scarpini E, De Stefano N, Prados F, Barkhof F.
    Neuroimage Clin; 2022 Apr; 35():103048. PubMed ID: 35598462
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study.
    Butzkueven H, Licata S, Jeffery D, Arnold DL, Filippi M, Geurts JJ, Santra S, Campbell N, Ho PR, REVEAL Investigators.
    BMJ Open; 2020 Oct 20; 10(10):e038861. PubMed ID: 33082194
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
    Baroncini D, Ghezzi A, Annovazzi PO, Colombo B, Martinelli V, Minonzio G, Moiola L, Rodegher M, Zaffaroni M, Comi G.
    Mult Scler; 2016 Sep 20; 22(10):1315-26. PubMed ID: 27230789
    [Abstract] [Full Text] [Related]

  • 10. Effects of Natalizumab and Fingolimod on Clinical, Cognitive, and Magnetic Resonance Imaging Measures in Multiple Sclerosis.
    Preziosa P, Rocca MA, Riccitelli GC, Moiola L, Storelli L, Rodegher M, Comi G, Signori A, Falini A, Filippi M.
    Neurotherapeutics; 2020 Jan 20; 17(1):208-217. PubMed ID: 31452082
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Safety and Efficacy of Fingolimod and Natalizumab in Multiple Sclerosis After the Failure of First-Line Therapy: Single Center Experience Based on the Treatment of Forty-Four Patients.
    Puz P, Lasek-Bal A.
    Med Sci Monit; 2016 Nov 10; 22():4277-4282. PubMed ID: 27829656
    [Abstract] [Full Text] [Related]

  • 16. Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom.
    Spelman T, Herring WL, Zhang Y, Tempest M, Pearson I, Freudensprung U, Acosta C, Dort T, Hyde R, Havrdova E, Horakova D, Trojano M, De Luca G, Lugaresi A, Izquierdo G, Grammond P, Duquette P, Alroughani R, Pucci E, Granella F, Lechner-Scott J, Sola P, Ferraro D, Grand'Maison F, Terzi M, Rozsa C, Boz C, Hupperts R, Van Pesch V, Oreja-Guevara C, van der Walt A, Jokubaitis VG, Kalincik T, Butzkueven H, MSBase Investigators.
    Pharmacoeconomics; 2022 Mar 10; 40(3):323-339. PubMed ID: 34921350
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.
    Lorscheider J, Benkert P, Lienert C, Hänni P, Derfuss T, Kuhle J, Kappos L, Yaldizli Ö.
    Mult Scler; 2018 May 10; 24(6):777-785. PubMed ID: 29685071
    [Abstract] [Full Text] [Related]

  • 20. Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.
    Barbin L, Rousseau C, Jousset N, Casey R, Debouverie M, Vukusic S, De Sèze J, Brassat D, Wiertlewski S, Brochet B, Pelletier J, Vermersch P, Edan G, Lebrun-Frenay C, Clavelou P, Thouvenot E, Camdessanché JP, Tourbah A, Stankoff B, Al Khedr A, Cabre P, Papeix C, Berger E, Heinzlef O, Debroucker T, Moreau T, Gout O, Bourre B, Créange A, Labauge P, Magy L, Defer G, Foucher Y, Laplaud DA, CFSEP and OFSEP groups.
    Neurology; 2016 Feb 23; 86(8):771-8. PubMed ID: 26826205
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.